# A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

> **NCT07282353** · PHASE3 · RECRUITING · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 135 (estimated)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** 2mg CS0159
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07282353
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-12-09
- **Final completion:** 2028-01-06
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282353, "A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07282353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*